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Abstract 
A wide variety of mitochondrial DNA (mtDNA) mutations have recently been identified in degenerative diseases of the brain, heart, 
skeletal muscle, kidney and endocrine system. Generally, individuals inheriting these mitochondrial diseases are relatively normal in early 
life, develop symptoms during childhood, mid-life, or old age depending on the severity of the maternally-inherited mtDNA mutation; 
and then undergo a progressive decline. These novel features of mtDNA disease are proposed to be the product of the high dependence of
the target organs on mitochondrial bioenergetics, and the cumulative oxidative phosphorylation (OXPHOS) defect caused by the inherited 
mtDNA mutation together with the age-related accumulation mtDNA mutations in post-mitotic tissues. 
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1. Mitoehondrial bioenergetics and biogenesis 
Mitochondrial OXPHOS plays a major role in human 
cellular bioenergetics through generation of energy in the 
form of ATP and by regulation of the cellular redox state 
via the reoxidation of NADH. Most human cells contain 
hundreds of mitochondria, and each mitochondrion con- 
tains multiple mtDNAs. The mtDNAs code for essential 
polypeptides of the OXPHOS pathway plus the structural 
RNAs for mitochondrial protein synthesis. Hence, deleteri- 
ous mutations of the mtDNA adversely affect cellular 
bioenergetics through the reduction in ATP availability 
and/or the increase in the cytosolic NADH/NAD + ratio. 
Mitochondrial OXPHOS is assembled within the mito- 
chondrial inner membrane from gene products encoded by 
both the nuclear DNA (nDNA) and mtDNA. The mtDNA 
encodes 13 polypeptides which include seven subunits 
(NDI, 2, 3, 4L, 4, 5, 6) of respiratory complex I 
(NADH:ubiquinone oxidoreductase), one subunit (cyto- 
chrome b, cytb) of respiratory complex III (ubiquinol:fer- 
ricytocbrome c oxidoreductase), three subunits (CO 1, CO2, 
and CO3) of respiratory complex IV (ferrocytochrome 
c:oxygen oxidoreductase), and two subunits (ATP6 and 8) 
of respiratory complex V (H+-translocating ATP synthase) 
(Fig. 1). In addition, complex I encompasses about 34 
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nDNA subunits, complex II (succinate:ubiquinone oxido- 
reductase) four nDNA subunits, complex II and IV include 
about 10 nDNA subunits, and complex V about 14 nDNA 
subunits. 
Complexes I to IV compose the electron transport chain 
in which electrons are collected from NADH by complex I 
and from succinate by complex II and transmitted to 
coenzyme Q (CoQ or ubiquinone). From CoQH 2 (reduced 
CoQ or ubquinol) the electrons are transmitted succes- 
sively to complex III, cytochrome c, complex IV, and 
finally oxygen to give water. The energy that is generated 
is used to pump protons across the mitochondrial inner 
membrane at complexes I, III, and IV. This electron 
transport chain-generated proton gradient can subsequently 
be dissipated by transport back through the ATP synthase 
proton channel with the energy that is released used to 
condense ADP and Pi to make ATP. The mitochondrial 
ATP is then exchanged for cytosolic ADP by the adenine 
nucleotide translocator (ANT) [1,2]. 
While most of the oxygen that is consumed by the 
mitochondrion is converted to water at complex IV, about 
4 to 5% of the oxygen picks up electrons directly from the 
flavin dehydrogenases and CoQH 2 to generate superoxide 
anion. Superoxide anion is converted to H202 by mito- 
chondrial manganese superoxide dismutase, and on to the 
highly reactive hydroxyl anion in the presence of transition 
metals. Inhibition of mitochondrial electron transport in- 
creases the electronegativity of the electron transport chain 
and accentuates the production of reactive oxygen species 
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[1-3]. These mitochondrial ly generated reactive oxygen 
species can then damage the mitochondrial membranes, 
proteins and DNA, further inhibit ing OXPHOS. 
The average human cell harbors thousands of mtDNA 
molecules. The mtDNA is a closed circular molecule of 
16 568 nucleotide pairs (nps) which is replicated from two 
origins, O H of the G-rich heavy (H)-strand and O L of the 
C-rich light (L)-strand, separated by 2 /3  of the mtDNA in 
the direction of H-strand replication. The mtDNA codes 
for 37 genes: the 13 OXPHOS polypeptides, 12S and 16S 
rRNAs, and 22 tRNAs that punctuate the polypeptide and 
rRNA genes (Fig. 1) [4]. 
The high copy number and cytoplasmic location of the 
mtDNA result in a unique genetics. The mtDNA is mater- 
nally inherited, and when a mutation arises in a mtDNA, it 
creates an intracellular mixture of mutant and normal 
molecules, known as heteroplasmy. As the cell undergoes 
mitotic or meiotic division, the mutant mtDNAs are ran- 
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Fig. 1. The human mtDNA map showing the location of the genes and common disease mutations. The polypeptide and rRNA gene identifiers are defined 
in the text. The punctuating tRNA genes are identified by their cognate amino acid, given in single letter code. Genes whose designators are outside the 
circle are encoded by the H-strand. Those whose designators are inside are encoded by the L-strand. The positions of the base substitution mutations which 
cause diseases are identified using a four or five letter clinical designator, the nucleotide position of the mutation, and the mutant base. The positions of 
two insertion-deletion mutations are shown by the outer arcs. For the diabetes mellitus and deafness insertion-deletion mutation, the 10.4 kb deletion is 
shown. It has the same breakpoint junction as the 6.1 kb insertion. 
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domly distributed into the daughter cells such that the 
mtDNA genotype drifts toward pure mutant or normal 
molecules, homoplasmy. The brain, heart, muscle, kidney 
and endocrine systems are highly reliant on mtDNA bio- 
energetics. Hence, as the mitochondrial bioenergetic capac- 
ity declines, it ultimately drops below the minimum thresh- 
old necessary for tissues to function and clinical manifesta- 
tions ensue [1,2,4]. 
The mtDNA has a much higher mutation rate than the 
nuclear genome. Both rearrangement and base substitution 
mutations occur in both germline and somatic tissues. 
Deleterious mutations in germline cells result in maternally 
transmitted iseases, while the accumulation of somatic 
mutations in post-mitotic tissues results in the progressive 
decline of mitochondrial bioenergetics during inherited 
disease progression and aging [1,2,4]. 
2. Diseases resulting from mtDNA rearrangements 
mtDNA rearrangements have been associated with the 
ocular myopathies including chronic progressive xternal 
ophthalmoplegia (CPEO) and the Kearns-Sayre Syndrome 
(KSS), the Pearson Marrow/Pancreas Syndrome, and 
adult-onset diabetes mellitus and deafness [1,2]. All of 
these conditions result from a single mutational event 
which occurred either in the female germline or early in 
development, and all progress with age. In the ocular 
myopathies disease progression has been associated with 
the age-related accumulation of deleted molecules in the 
post-mitotic muscle [5] due to the clonal expansion of the 
deleted molecules in segmental zones of the muscle fibres. 
These segmental zones experience a proliferation of abnor- 
mal mitochondria which stain red by Gomori trichrome, 
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Fig. 2. Diabetes, deafness and stroke pedigree. 
giving the characteristic ragged red muscle fibres (RRFs) 
[6,7]. 
A similar pathophysiological mechanism ay underlie 
the late-onset and progression of maternally-inherited dia- 
betes mellitus and deafness resulting from a complex 
mtDNA rearrangement [8,9]. We first demonstrated that 
mtDNA mutations can cause adult-onset (Type II) diabetes 
in a large three generation pedigree (Fig. 2). The mother 
(I-2) transmitted her diabetes and deafness to all of her 
offspring in two separate; marriages and her daughters, but 
not her sons, transmitted the disease to the next generation. 
The proband (II-1) and her mother (I-1) also experienced 
strokes involving cortical and subcortical structures. 
Four maternal relatives were muscle biopsied. All had 
significant defects in OXPHOS, but none exhibited RRFs. 
Endocrine analysis of two of the proband's brothers who 
are prone to diabetic ketoacidosis (II-4 and 1I-5) revealed 
that one of the brothers produced normal evels of insulin 
during euglycemia, while the other had very low levels of 
euglycemic insulin production. Following sustacal-induced 
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Fig. 3. Endocrine function of mitochondrial diabetes and deafness patients. The time is given in minutes relative to sustacal challenge. 
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Fig. 4. Duplicated, deleted and normal mtDNA is maternally-transmitted 
diabetes mellitus and deafness. Skeletal muscle DNA from the proband's 
daughter (individual III-1 of Fig. 2) (Lanes 4-7) and leukocyte DNA 
from a control (Lanes 1-3) were digested with various restriction en- 
donucleases, the fragments eparated on an agarose gel, and the Southern 
blot hybridized with total mtDNA probe [9]. 
hyperglycemia, both brothers failed to respond by increas- 
ing insulin release or decreasing lucagon release. Thus, 
both brother had a defect in their pancreatic ~ and /3 cell 
glucose sensors (Fig. 3). 
Analysis of the mtDNAs of multiple maternal relatives 
revealed that all harbored a complex mtDNA rearrange- 
ment involving related deleted and inserted mtDNA 
molecules co-inherited with normal moleculars in a unique 
trimolecular heteroplasmy. This was demonstrated by the 
Southern analysis of the mtDNA from the proband's 
daughter (III-1), as compared to a normal control (Fig. 4). 
Undigested control mtDNAs gave two bands, a slower- 
migrating (upper) supercoiled form and a faster-migrating 
(lower) nicked and linear 16.5 kb form (Lane 1). Undi- 
gested patient mtDNA, by contrast, gave six bands, three 
upper and three lower, with the middle band of each set of 
three bands corresponding to the control band (Lane 4). 
Hence, this patient harbors, in addition to the normal 
mtDNA, both a larger (duplicated) and a smaller (deleted) 
mtDNA molecules. Digestion of the control's mtDNA with 
either BamHI (single site at np 14258) (Lane 2) or PvulI 
(single site at np 2650) (Lane 3) linearized all of the 
mtDNA to give a 16.5 kb fragment. By contrast, digestion 
of the patient's mtDNA with BamHI (Lane 5) or SnaBI 
(single site at np 10734) (Lane 6) cleaved the top two 
bands of the upper triplet and enhanced the upper two 
linear bands of the lower triplet. However, the lowest of 
the upper three bands remained intact. This demonstrated 
that the top two bands of the patient's upper triplet each 
contained one BamHI and one SnaBI site, but that this 
region was deleted in the lower band of the upper triplet. 
Digestion of the patient's mtDNAs with PvulI reduced all 
of the bands to two fragments, a 16.5 kb full length linear 
fragment and a smaller 6.1 partial fragment (Lane 7). This 
demonstrates that the patient's duplicated mtDNA must 
harbor two PvulI sites separated by 6.1 kb and that both 
the duplicated and deleted molecules must share the same 
6.1 kb region of the mtDNA. Further, the patient's undi- 
gested deleted mtDNA (Lanes 4-6) migrates at about 12 
kb, suggesting that it is a dimer of 6.1 kb fragments. 
Sequence analysis of the duplicated and deleted molecules 
revealed that the molecules hared the same breakpoint 
junction, which was flanked by a 10 np direct repeat. 
Hence, these molecules must have generated a common 
original event [8,9]. 
Analysis of the proportions of normal, duplicated and 
deleted molecules in the muscle and blood cells of multi- 
ple maternal relatives revealed that these tissues had all 
three molecular forms, but the relative proportion varied 
between individuals and tissues. Moreover, the deletion 
was favored in the post-mitotic muscle tissue, while the 
duplicated molecule was favored in the mitotically active 
blood cells. Propagation of lymphoblastoid cell lines from 
three patients resulted in the loss of the deleted molecules 
and enrichment of the duplicated molecules [9]. These 
observations suggest hat the duplicated molecule may be 
the maternally transmitted form and that the duplicated 
molecule is converted to the deleted molecule over time in 
post-mitotic tissues. If this model is correct, then it is the 
progressive accumulation of the deleted molecules with 
age that erodes tissue energy metabolism, ultimately cross- 
ing expression thresholds and causing tissue and organ 
failure. 
Complex mtDNA rearrangements have also been ob- 
served in the ocular myopathies [10], and a similar mtDNA 
duplication has been reported in a family with ocular 
myopathy and diabetes [11]. Moreover, diabetes and deaf- 
ness has also been associated with the tRNA Leu(UUR) muta- 
tion at np 3243 [the MELAS (mitochondrial encephalomy- 
opathy, lactic acidosis and stroke-like pisodes) mutation] 
in a large maternal pedigree [12] as well as in a portion of 
randomly selected Type II diabetes patients [13]. Hence, 
OXPOS defects caused by the inheritance of complex 
mtDNA rearrangements and mtDNA point mutations are 
an important mechanism for producing diabetes mellitus. 
Maturity-Onset Diabetes of the Young (MODY) has 
also been linked to mutations in the pancreatic /3 cell 
glucokinase gene. Glucokinase has a higher K m than other 
cellular hexokinases, and is only active when serum glu- 
cose levels are high. Hence, glucokinase provides the 
glucose sensor for the pancreas endocrine system. MODY 
mutations increase the glucokinase K m, inactivating the 
glucose sensor and rendering individuals unable to respond 
to hyperglycemia with increased insulin production [14- 
16]. Recently, pancreatic glucokinase has been shown to 
be predominantly bound to the mitochondrial outer mem- 
brane through the outer membrane pore protein porin. 
Porin is thought o interact with the inner membrane ANT, 
permitting rapid exchange of ATP and ADP between the 
matrix and the cytosol. The resulting macromolecular corn- 
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Glucose bly the age-related accumulation of somatic mtDNA muta- 
tions in the beta cells. The linkage of diabetes mellitus to 
two very different mtDNAs mutations uggests that defects 
in OXPHOS may be a common cause of diabetes. 
3. Diseases resulting from mtDNA base substitutions 
H+ AII" 
Complex V 
Fig, 5. Cellular energetics and glucose sensing. 
MtDNA nucleotide substitution mutations can adversely 
affect either polypeptide genes or protein synthesis (tRNA 
and rRNA) genes. Deleterious polypeptide missense muta- 
tions which occur in the H+-translocating ATP synthase 
(complex V) have been associated with neurogenic muscle 
weakness, ataxia, and retinitus pigmentosa (NARP) as well 
as the Leigh's syndrome; while missense mutations that 
alter the subunits of the electron transport chain (com- 
plexes I, III, and IV) frequently cause a form of mid-life, 
acute-onset, central vision loss called Leber's hereditary 
optic neuropathy (LHON) and/or dystonia [2,19,20]. 
MtDNA tRNA mutations are frequently associated with 
RRFs and include the np 3242 mutation of the MELAS 
syndrome and the np 8344 mutation in tRNA ky~ of the 
myoclonic epilepsy and ragged red fiber (MERRF) dis- 
ease. A mtDNA 12S rRNA mutation at np 1555 has been 
associated with deafness, both maternally-inherited and 
aminoglycoside-induced [19,20]. 
plex within the pancreatic /3 cell of glucokinase, porin, 
ANT and H+-translocating ATP synthase (Fig. 5) would 
link the cytosolic glucose concentration with mitochondrial 
ATP production, through the two substrates of glucoki- 
nase, glucose and ATP. In this manner, the glucose sensor 
would be sensitive to mutations in either glucokinase or 
the mtDNA OXPHOS genes [9,17,18]. 
The insertion-deletion, diabetes and deafness pedigree 
demonstrates that adult-onset diabetes and deafness can 
result from mtDNA mutations, and suggests that the de- 
layed onset of the insulin defect could be the result of the 
age-related accumulation of deleted mtDNAs in the post- 
mitotic target tissue. The predilection to diabetes and 
deafness caused by the np 3243 tRNA Leu(uvR) mutation 
must also be the result of the inheritance of a partial 
OXPHOS defect. However, the delayed-onset of the dis- 
ease must be the product of some secondary factor, possi- 
3.1. Neurodegenerative disease caused by the ATP6 np 
8993 mutation 
A T to G transversion at np 8993 converts the highly 
conserved leucine 156 in the ATP6 gene to an arginine. 
This mutation is invariably heteroplasmic and has been 
shown to cause a spectrum of clinical manifestations [21]. 
This is clinical variability is exemplified by one three 
generation pedigree (Fig. 6) in which the proband (IV-3) 
presented at 18 months with subacute necrotizing en- 
cephalopathy (Leigh's syndrome) and associated basal 
gangliar degeneration. His brother (IV-2) exhibited cere- 
bellar dysfunction, and his half brother (IV- 1) through his 
mother died of Leigh's syndrome at age 5 1/2 years. Their 
mother (111-4), grandmother (11-4) and two maternal aunts 
(III-1 and Ili-2) all had salt-and-pepper retinopathy and 
migraine, while the proband's great uncle (II-1) presented 
Table 1 
OXPHOS capacity of isolated mitochondria from lymphoblasts and rho ° transformants carrying the mtDNA 8993 T ~ G mutation 
State III State IV ADP/O + DNP I I I /DNP 
Lymphoblasts 
Controls (n = 9) 164 4- 27 57 4- 19 2.55 _+ 0.14 174 4- 28 0.88 _+ 0.02 
8993 T ~ G (n = 2) 101 _+ 28 71 _+ 42 1.78 4- 0.40 193 4- 35 0.52 _ 0.06 
Cybrids 
Controls (n = 3) 75 _+ 5.6 20 _+ 2.9 2.35 4- 0.09 86 4- 7.8 0.92 _+ 0.07 
8993 WT (n = 3) 70 4- 21.7 17 4- 2.5 2.32 _+ 0.12 81 4- 30 0.88 _+ 0.07 
8993 T ~ G (n = 5) 44 _+ 8.7 22 _+ 3.9 1.70 4- 0.30 83 4- 22 0.54 _+ 0.05 
Substrate is pyruvate + malate. 
146 D.C. Wallace et al. / Biochimica et Biophysica Acta 1271 (1995) 141-151 
I 1~ 
II 1~-2~ 3[ -- ] 
I l l  1 ~ 4  
IV 
[] 
• OPCA + liP [] Leigh Syndrome [] Unaffected 
RP [] Early cerebellar dysfunction 
Fig. 6. OPCA + RP and Leigh syndrome associated with mtATP68993 
mutation. 
with mental retardation, hearing loss, macular degenera- 
tion, and olivopontocerellar at ophy on MRI [22]. 
The biochemical defect associated with the np 8993 T 
to G mutation was indentified by quantitating mito- 
chondria respiration from two patient lymphoblastoid cell 
lines (Table 1). When oxidizing NADH-linked substrates, 
the state IV and uncoupler dinitophenol (DNP)-stimulated 
respiration rates of the patient and control ymphoblastoid 
cell lines were essentially the same. However, the ADP- 
stimulated state III respiration rate of the patient cell lines 
was 38% less than the controls, reducing the state 
III/DNP-stimulated rate ratio by 40% (Table 1, upper two 
lines). This implies that these patients harbor a defect in 
the proton channel of their H +-translocating ATP synthase, 
a conclusion supported by a 30% reduction in the ADP/O 
ratio of the patient mitochondria [23]. 
To confirm that the observed efect was the product of 
the np 8993 T to G mutation, the mitochondria nd 
mtDNAs of the patient's lymphoblasts were transferred to 
a different nuclear background by the cytoplasmic hybrid 
or cybrid method [24]. The patient lymphoblastoid cells 
were enucleated by incubation in cytochalasin B and cen- 
trifugation in a percoll gradient. The resulting cytoplasts 
containing the patient's mitochondria nd mtDNAs were 
then fused by electric shock to human osteosarcoma cells 
which had previously been depleted of their mtDNAs by 
extended cultivation in eithidium bromide [25]. Cybrids 
were isolated by selecting for the osteosarcoma cell's 
thymidine kinase (TK)-deficient nuclei by growth in bro- 
modeoxyuridine (BrdU) and for acquisition of the patient's 
mitochondria by growth in the absence of uridine. Trans- 
mitochondrial cybrids were clonally isolated and tested for 
their mtDNA genotype. Since the patient's donor cell lines 
were heteroplasmic atnp 8993, some of the cybrid clones 
were found to be homoplasmic for the mutant base (G), 
while others were homoplasmic for the normal base (T). 
The complex V activities of these cybrids were then 
compared to each other and to comparable cybrids pre- 
pared using normal lymphoblastoid cell lines as cytoplas- 
mic donors (Table 1, lines 3-5). As with the lymphoblas- 
toid cell lines, the state IV and DNP-uncoupled rates of the 
patient and control transmitochondrial cybrid cell lines 
were all comparable. Similarly, the ADP-stimulated state 
III rates, state I I I /DNP ratios and ADP/O ratios were 
comparable for the control cybrids and the patient cybrids 
that were homoplasmic for normal base (T) at np 8993. By 
contrast, the state III rates of the patient cybrids which 
inherited the mutant G at np 8993 were reduced 37% and 
the state I I I /DNP ratios were reduced 41% relative to 
those of control cybrids and the patient cybrids which had 
acquired mtDNAs with the normal base. The ADP/O 
ratios of the cybrids with the mutant base were similarly 
reduced by 27% relative to control cybrids and patient 
mitochondria with the normal base. Thus the patient de- 
fects in the state Ili (ADP-stimulated) respiration and 
ADP/O ratio are linked to and solely the consequence of
the np 8993 T to G mutation [23]. 
These studies prove that a single nucleotide change can 
specifically reduce the efficiency of mitochondrial energy 
production, and have profound effects on the physiology 
and integrity of the brain. Consequently, these studies 
prove that systemic mitochondrial bioenergetic defects can 
lead to tissue-specific degenerative diseases. 
3.2. LHON and dystonia caused by electron transport 
chain mutations 
LHON is most commonly associated with four primary 
mtDNA mutations. In order of severity and frequency, 
these are np 11778, np 3460, np 14484, and np 15257. The 
most common cause of LHON is a mutation in the ND4 
gene at np 11778. This G to A transition converts the 
highly conserved arginine 340 to a histidine and accounts 
for about 50% of European LHON cases [26]. In rare 
instances, the np 11778 mutation has been associated with 
adult-onset rigidity and bilateral basal ganglia degeneration 
[27], suggesting that mtDNA missense mutation can cause 
movement disorders and that the np 11778 mutation is the 
most severe of the common LHON mutations. The next 
most common cause of LHON is a mutation in the ND1 
gene at np 3460. This G to A transition converts the 
moderately conserved alanine 52 to a threonine [28,29]. A 
comparably frequent, but still milder mutation is the ND6 
mutation at np 14484. This T to C transition converts the 
mildly conserved methionine 63 to a valine [30]. The least 
severe of the primary LHON mutations is the cytb muta- 
tion at np 15257. This G to A transition converts the 
highly conserved asparate 171 to an asparagine [31]. To- 
gether, these mutations account for over 80% of LHON 
cases. 
mtDNA haplotype analysis of LHON patients harboring 
the four common primary mutations has demonstrated that 
the np!  1778 and 3460 mutations have occurred multiple 
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times giving rise to LHON, and that these mutations how 
little if any association with particular mtDNA haplotypes 
[32,33]. By contrast, the np 14484 and 15257 mutations are 
most frequently associated with a particular mtDNA lin- 
eage defined by nucleotide substitutions at np 4216 and 
13708. The np 4216 mutation converts a unconserved 
tyrosine to a histidine, while the np 13708 mutation con- 
verts a moderately conserved alanine to a threonine [19]. 
The np 14484 mutation appears to have arisen in this 
mtDNA lineage several independent times and consistently 
resulted in LHON. The np 15257 mutation appears to have 
arisen once in this mtDNA lineage [33] and once in an 
unrelated mtDNA lineage [34]. In the np 4216 and np 
13708 lineage, the np 15257 is frequently associated with 
the np 14484 mutation. It has also been associated with a 
heteroplasmic G to A transition at np 5244 which converts 
the totally conserved glycine 259 in the ND2 gene to a 
serine [31], but has been found in other patients without 
other identifiable pathogenic mutations [33]. Hence, the np 
14484 and np 15257 mutations appear to be enhanced in 
their pathogenicity by a synergistic interaction with other 
mild LHON mutations and by certain background mtDNA 
haplotypes [19,20,33]. 
In addition to these LHON mutations, we have recently 
identified a more severe electron transport chain mutation 
which can cause either LHON or severe generalized ysto- 
nia. This G to A transition at np 14459 in the ND6 gene 
converts the highly conserved alanine 72 to a valine [35]. 
The mutation was first indentified in a large Hispanic 
family (Fig. 7) in which both adolescent-onset LHON and 
childhood-onset dystonia were found among maternal rela- 
tives. For the dystonic hildren, the mean age of onset was 
4 years, and asymmetric dystonic rigidity and pseudobul- 
bar syndrome were associated with symmetrical basal gan- 
gliar lesions on MRI [36]. Overall, 19% of the 42 maternal 
relatives manifested LHON, 31% presented with dystonia, 
and 2% exhibited both LHON and dystonia. Moreover, 
LHON predominated in the early generations of this pedi- 
gree, while dystonia came to predominate in later genera- 
tions [36]. The proband with dystonia (IV-36), whose 
mtDNA was sequenced, was homoplasmic for this muta- 
tion, as was her dystonic half brother (IV-35). However. 
V 
IV  
111 
12 11 
36 
35 
34 
33 
32 
o 
31 
8 
7 . 
,o 
11 
30 
29 
) 27 
~26 
12 
13 
11 
g 
[ ]  O HEREDITARY NEURORETINOPATHY 
(L~ber's disease) 
• • NEURODEGENERATIVE DISORDER 
(~ OBLIGATE CARRIER 
Fig. 7. LHON and dystonia pedigree from Ref. [36]. 
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their mother with LHON was heteroplasmic, suggesting 
that the severity of the phenotype might be a function of 
the proportion of mutant mtDNAs in the target organs. 
Comparison of the mtDNA haplotype of this family with 
the mtDNA haplotypes commonly found in the various 
continents revealed that the np 14484 mutation in the 
family had arisen on a Native American haplogroup B 
mtDNA, consistent with the Hispanic origin of the family 
[35]. Screening additional LHON and dystonia patients for 
this mutation revealed two additional cases, an indepen- 
dent LHON pedigree and in an isolated dystonia case. The 
LHON pedigree involved an affected mother and daughter, 
with an MRI of the daughter revealing basal ganglia 
lesions. Skeletal muscle mitochondria OXPHOS enzyme 
analysis revealed a complex I defect consistent with the 
ND6 mutation. The dystonic child exhibited symmetrical 
bilateral basal ganglia degeneration, but had no other 
family history. The mtDNAs from these families were not 
of Native American origin, confirming that the np 14459 
mutation has arisen multiple times and that the different 
clinical presentations are the product of the mutation and 
not the background mtDNA haplotype [37]. 
The np 14484 and np 14459 LHON mutations both 
occur in the ND6 gene and are only nine codons apart, yet 
the np 14484 mutation is associated only with LHON and 
the np 14459 mutation with LHON and dystonia. These 
mutations occur in the most highly conserved region of 
ND6. Comparison of the sequence conservation of these 
two codons (Fig. 8) revealed that the np 14484 mutation 
substitutes a valine for a methionine which is conserved 
only in human and bovine, but the np 14459 mutation 
substitutes a valine for an alanine which is conserved from 
human to sea urchin and for which either an alanine or a 
serine is present in all species that have been examined. 
This suggests that the severity of a mtDNA mutation can 
markedly effect the clinical manifestations of the disease, 
and that the more sever electron transport chain missense 
mutations can preferentially affect the basal ganglia and 
impair motor control. 
Since the relatively sever np 14459 mutation causes 
pediatric onset movement disorders, it follows that milder 
mtDNA mutations might cause later-onset disease. Support 
for this hypothesis has been supported by screening 
Alzheimer and Parkinson disease patients for potentially 
deleterious mtDNA mutations. 
3.3. Alzheimer and Parkinson disease associated mtDNA 
mutations 
A collection of 74 neuropathologically confirmed 
Alzheimer disease or Alzheimer plus Parkinson disease 
brains were screened for associated mtDNA sequence vari- 
ants by regional polymerase chain reaction (PCR) amplifi- 
cation and high density restriction endonuclease analysis. 
Three mutations were identified which may contribute to 
the etiology of these diseases. The first was a base substi- 
tution in the tRNA Gin at np 4336 which converted a 
moderately conserved G to a A at the intersection between 
the amino acid acceptor and T~0C stems. This mutation 
was found in 5% of patients, as compared to 0.4% of 
controls, and defined a Caucasian mtDNA lineage at in- 
creased risk for Alzheimer and Parkinson disease. The 
second mutation was an ND1 missense mutation at np 
3397. This mutation converted a highly conserved methio- 
nine to a valine, and was found in two independent 
mtDNA haplotypes, one within the tRNA Cln np 4336 
mtDNA lineage and the other outside. In both instances, 
this mutation was associated with more than one affected 
maternal relative. The third mutation was an approximately 
five nucleotide insertion in the 12S rRNA gene between 
nps 956 and 965. This novel mutation was also found in a 
the np 4336 mtDNA lineage. The accumulation of addi- 
tional deleterious mtDNA mutations in the Alzheimer and 
Parkinson disease-prone tRNA GIn mtDNA lineage, is remi- 
Amino Acid Position 
60 61 62 63 6 4 65 66 67 68 69 70 71 7 2 73 74 75 76 
LHON + Dystonia (USA) L G G M M v v F G Y T T V M A I E 
LHON L G G M V v v F G Y T T A M A I E 
Human L G G M M v v F G Y T T A M A I E 
Cow L G G M M v v r G Y T T A M A T E 
Fin whale L G G M L v v F G Y T T A M A T E 
Mouse L G G M L v v F G Y T T A M A T E 
Rat L G G M t v v F G Y T T A M A T E 
Xenopus L G G M t V v F A Y S A A R A K 
Sea Urchin I G G M L v v F P Y S S A I S P E 
Chicken L G G M L v v F V Y S V S L A A D 
Quail L G G M L v v F V Y S V S L A A D 
Fruit fly L G G M L v L F I Y V T S L A S N 
C. elegans L S G I F v I L V Y F S S L S K I 
A. suum L S G I F V I L V Y F S S L S K I 
Fig. 8. Evolutionary conservation of ND6 codon 64 
14484 LHON mutation of codon 72 altered by the np 
dystonia mutations. 
altered by the np 
14459 LHON and 
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Table 2 
Age-related mtDNA damage in Alzheimer's disease and control brains 
149 
Frontal cortex All cortex 
< 75 year > 75 year > 75 /< 75 < 75 year > 75 year > 75 /< 75 
Controls 0.00096 + 0.0008 0.011 _+ 0.010 11 0.00072 _+ 0.00071 
n = 12 n = 7 n = 19 
AD 0.012 _+ 0.015 0.0025 + 0.002 0.21 0.011 + 0.013 
n= 10 n= 10 n=27 
AD/Control 13 0.23 15 
0.012 _+ 0.01 17 
n=17 
0.0026 _+ 0.0022 0.24 
n = 27 
0.22 
niscent of the clustering of potentially pathologic muta- 
tions in LHON lineages, and suggests that these mutations 
may synergistically interact to increase to probability of 
clinical manifestation [38]. 
4. Somatic mtDNA mutations in aging and disease 
progression 
These studies demonstrate that maternally-inherited 
mtDNA mutations can predispose individuals to a spec- 
trum of neurodegenerative diseases, with the severity of 
the mutation correlating with the age of onset of the 
disease. However, all maternally transmitted mtDNA mu- 
tations are present at birth, so some additional factor must 
account for the delayed onset of the symptoms. That factor 
is likely to be the age-related accumulation of somatic 
mtDNA mutations in post-mitotic tissues. These would 
progressively erode the patient's mitochondrial OXPHOS 
capacity untill it drops below tissue-specific bioenergetic 
thresholds leading to disease. 
Analysis of mitochondrial OXPHOS enzymes in post- 
mitotic tissues has revealed that the specific activities of 
the respiratory complexes decline with age [39,40]. This 
decline has been correlated with the progressive accumula- 
tion of somatic mtDNA mutations in post-mitotic tissues. 
For example, quantitation of the common 5 kb mtDNA 
deletion in normal brain has revealed that the cerebellum 
accumulates relatively little mtDNA damage with age. By 
contrast, the various cortical regions of the brain accumu- 
late appreciable mtDNA damage after age 75 (Table 2), 
and the basal ganglia accumulates the highest levels of 
somatic mtDNA mutations, with over 10% of the basal 
ganglia mtDNAs containing the 5 kb deletion by age 80 
[41,42]. 
If the somatic accumulation of mtDNA mutations is the 
precipitating factor in mtDNA diseases, then the severity 
of the inherited mtDNA mutation would set the initial 
bioenergetic capacity at birth and thus the relative age of 
onset of the disease. Individuals with an initially high 
mitochondrial bioenergetic capacities would require exten- 
sive somatic mtDNA damage to cross expression thresh- 
olds and thus remain functional until late in life, while 
individuals which inherit significantly deleterious mtDNA 
mutations would start at a lower initial capacity and re- 
quire fewer somatic mtDNA mutations to have the same 
effect and would develop symptoms earlier (Fig. 9). 
This differential effect of the somatic mutation-induced 
bioenergetic decline in mitochondrial disease patients could 
be further accentuated by an elevation of the mtDNA 
somatic mutation rates in individuals with partial OX- 
PHOS defects. One cause of somatic mtDNA mutations is 
100 
Normal 
! ! fPat ient  * 
0 50 100 AGE 0 50 100 AGE 
% OXPHOS capacity ~ % Damaged mtDNA 
(arbitrary units) 
Fig. 9. Hypothesis proposing the relationship between OXPHOS diseases and aging. The cumulative genetic load resulting from inherited (germline) and 
acquired (somatic) mutations i shown in the right panel. The associated age-related decline in OXPHOS relative to clinical expression thresholds i shown 
in the right panel. 
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mitochondrially-generated reactive oxygen damage, which 
is increased when OXPHOS is inhibited. The importance 
of reactive oxygen species for mtDNA damage has been 
dramatically demonstrated in patients with chronic cardiac 
ischemia nd reperfusion due to atherosclerotic plaques in 
their coronary arteries. In these patients, as the partially 
occluded coronary artery constricts, the heart mitochondria 
are deprived of oxygen, while retaining an excess of the 
reducing substrates, fatty acids and carbohydrates. Conse- 
quently, the electron transport chain becomes fully re- 
duced. On subsequent dilation of the coronary artery, the 
heart issue is rapidly reperfused with oxygen, thus pulling 
the excess electrons directly from the reduced flavo- 
proteins and ubiquinol generating reactive oxygen species. 
Within one minute of repurfusion, 95% of the highly-reac- 
tive hydroxyl radical is present in the mitochondria in 
model systems [43]. 
Quantitation of the common 5 kb mtDNA deletion in 
hearts from normal subjects and patients with chronic 
ischemia and reperfusion demonstrated that the ischemic 
hearts had a markedly increased level of mtDNA deletions 
relative to age-matched controls. The hearts of normal 
subjects accumulated little mtDNA damage up to age 30, 
and subsequently experienced a slow but steady increase in 
mtDNA deletions. By contrast, the chronically ischemic 
hearts accumulated between 8- and 2000-fold higher dele- 
tion levels than the age-matched controls. Individuals who 
died of acute cardiac disease have less deletions than those 
with chronic illness suggesting that the effect is cumulative 
[44,45]. These results support he conclusion that reactive 
oxygen damage is an important cause of mtDNA damage 
and mutations. 
While ischemia inhibits electron transport by removing 
the terminal electron acceptor, mtDNA mutations block 
electron transport by inactivating one or more of the 
respiratory complexes. Thus, deleterious mtDNA muta- 
tions would also increase the electronegativity of the of the 
initial steps of the electron transport chain, increasing the 
potential for reactive oxygen species generation and so- 
matic mtDNA damage. 
To determine if increased somatic mtDNA mutations 
are associated with progressive neurodegenerative dis- 
eases, we have quantitated the levels on the common 5 kb 
deletion in the brains of Alzheimer disease patients (Table 
2). We found that the cortical regions of the brains of 
patients who died prior to age 75 had over 15-fold more 
mtDNA deletions than comparably aged controls. This 
demonstrates that Alzheimer disease brains do have in- 
creased levels of somatic mtDNA mutations. By contrast, 
the cortical regions of Alzheimer's disease patients who 
died after age 75 had only one quarter of the deletion 
levels of age-matched controls [46]. While we still do not 
know why the mtDNA deletion levels decline in older 
Alzheimer disease brains, one possibility is that the mutant 
mtDNAs are clonally expanded in the neurons in which 
they occur, in a manner analogous to the regional expan- 
sion of the deleted mtDNA is muscle segments of KSS 
patients. If this is the case, then the level of deletion would 
accumulate within the neuron until there was insufficient 
mitochondrial bioenergetic apacity to sustain viability, 
thus causing the neuron to die. When the neuron dies the 
resident deleted mtDNAs would be lost resulting in a 
decline in the average deletion levels. Thus, the decline in 
deleted mtDNA may be an indicator of the neuronal 
dysfunction and death responsible the age-related dementia 
Alzheimer's disease patients. 
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